Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cellmid Ltd announces new findings presented at 3rd Midkine Symposium in Kyoto

Wednesday, 30 Apr 2014 12:21am EDT 

Cellmid Ltd:Says its 3rd Midkine Symposium concluded successfully with new findings on midkine (MK) biology, manufacture and clinical utility.Held in Kyoto, Japan, discoverers of MK, Emeritus Professor Takashi Muramatsu and Professor Kenji Kadomatsu, co-hosted the event.3rd MK Symposium built on the success of the first two MK conferences held in Sydney (2010) and Istanbul (2012), and attracted scientists from eleven countries.Cellmid’s MK protein programs serum-stable, drug-like MK manufacture has been achieved at large scale for clinical use by one of the company’s commercial partners.Cellmid’s anti-midkine antibodies have been shown to overcome drug-resistance in the deadly brain cancer glioma in pre-clinical efficacy studies conducted by Dr Guillermo Velasco (Complutense University, Madrid, Spain).Cellmid’s anti-MK antibody enhanced bone fracture healing in vivo in animal studies conducted by Dr Astrid Liedert (University of Ulm, Germany).New insights were presented into MK’s molecular structure and its functional implications by Professors Christoph Winkler (National University of Singapore) and Licheng Dai (Huzhou Hospital, Zhejiang Provence, China). 

Company Quote

27 Jul 2015